Madrigal Pharmaceuticals: Boom Or Bust In MASH? Regretfully, I'm Bearish
Madrigal Pharmaceuticals receives a Sell rating due to high valuation and increasing competition in the MASH treatment space, despite strong initial sales of its drug Rezdiffra. The company reported $958.4 million in 2025 revenue but remains unprofitable as operating expenses continue to rise. With rising SG&A and R&D costs expected in 2026 and no clear revenue guidance, near-term softness is anticipated. While pipeline developments and M&A speculation provide potential upside, market saturation and leadership uncertainty weigh on long-term prospects after a 280% stock run over five years.
- ▪Rezdiffra generated $958.4 million in sales in 2025, treating approximately 36,250 patients.
- ▪Madrigal remains unprofitable as operating expenses outpace revenue growth.
- ▪SG&A and R&D expenditures are projected to increase in 2026 without specific company guidance.
- ▪Consensus estimates suggest potential revenue softness in Q1 2026.
- ▪Intensifying competition in the MASH therapeutic area raises concerns about Rezdiffra's long-term market dominance.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Earnings Analysis","item":"https://seekingalpha.com/earnings/earnings-analysis"},{"@type":"ListItem","position":3,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4895251-madrigal-pharmaceuticals-boom-or-bust-in-mash-regretfully-im-bearish"},"author":{"@type":"Person","name":"Edmund…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
